DK0556329T3 - Substituerede piperaziner som midler til behandling af centralnervesystemet - Google Patents

Substituerede piperaziner som midler til behandling af centralnervesystemet

Info

Publication number
DK0556329T3
DK0556329T3 DK92901210.2T DK92901210T DK0556329T3 DK 0556329 T3 DK0556329 T3 DK 0556329T3 DK 92901210 T DK92901210 T DK 92901210T DK 0556329 T3 DK0556329 T3 DK 0556329T3
Authority
DK
Denmark
Prior art keywords
nervous system
central nervous
agents
treatment
substituted piperazines
Prior art date
Application number
DK92901210.2T
Other languages
Danish (da)
English (en)
Inventor
Shelly Glase
Sarah Jane Smith
Lawrence David Wise
Juan Carlos Jaen
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0556329T3 publication Critical patent/DK0556329T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK92901210.2T 1990-11-05 1991-10-29 Substituerede piperaziner som midler til behandling af centralnervesystemet DK0556329T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60930090A 1990-11-05 1990-11-05
US07/778,247 US5270312A (en) 1990-11-05 1991-10-24 Substituted piperazines as central nervous system agents

Publications (1)

Publication Number Publication Date
DK0556329T3 true DK0556329T3 (da) 1996-05-06

Family

ID=27086004

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92901210.2T DK0556329T3 (da) 1990-11-05 1991-10-29 Substituerede piperaziner som midler til behandling af centralnervesystemet

Country Status (11)

Country Link
US (1) US5270312A (fr)
EP (1) EP0556329B1 (fr)
JP (1) JP3064418B2 (fr)
AT (1) ATE132855T1 (fr)
AU (1) AU645873B2 (fr)
CA (1) CA2094703C (fr)
DE (1) DE69116378T2 (fr)
DK (1) DK0556329T3 (fr)
ES (1) ES2084996T3 (fr)
GR (1) GR3019490T3 (fr)
WO (1) WO1992007832A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
AU780009B2 (en) * 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
JP2008520647A (ja) * 2004-11-16 2008-06-19 ニューロケム （インターナショナル） リミテッド Ｃｎｓおよびアミロイド関連疾患治療のための化合物
CA2900876A1 (fr) 2004-12-22 2006-08-17 Bhi Limited Partnership Methodes et compositions de traitement de maladies liees a l'amyloide
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
WO2008019394A2 (fr) * 2006-08-11 2008-02-14 The Government Of The United States Of America As Represented By The Secretary, Dept Of Health And Human Services Méthodes de traitement et de diagnostic de troubles psychiatriques
WO2009019534A2 (fr) 2006-10-12 2009-02-12 Bellus Health (International) Limited Procédés, composés, compositions et véhicules permettant de délivrer l'acide 3-amino-1-propane sulfonique
US20110178024A1 (en) 2008-09-29 2011-07-21 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
CN103980129B (zh) * 2010-11-05 2016-08-31 日本欧爱特农业科技株式会社 乙炔基苯脒化合物或其盐、其制备方法和用于农业和园艺的杀菌剂
CN104163813B (zh) * 2013-05-16 2017-02-01 广东东阳光药业有限公司 取代的吲哚化合物及其使用方法和用途
CN104337812B (zh) 2013-07-29 2018-09-14 广东东阳光药业有限公司 取代的杂芳基化合物及其使用方法和用途
CN106243088B (zh) 2015-06-03 2019-01-04 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途
CA3066077A1 (fr) 2017-06-07 2018-12-13 Adrx, Inc. Inhibiteur d'agregation de tau
CA3073062A1 (fr) 2017-08-18 2019-02-21 Adrx, Inc. Inhibiteurs peptidiques d'agregation de tau

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545561A1 (de) * 1965-08-23 1969-12-11 Acraf Verfahren zur Herstellung von pharmakologisch aktiven N,N-disubstituierten 1-Aryl-3-aminopropinen
GB1055548A (en) * 1965-08-23 1967-01-18 Acraf New substituted 1-aryl-3-aminopropynes and process for their preparation
US3856790A (en) * 1970-01-06 1974-12-24 American Home Prod Cyclic amides of 1,4-diaminobut-2-yne
ES8802151A1 (es) * 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
US4891375A (en) * 1988-01-13 1990-01-02 Pfizer Inc. Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4935424A (en) * 1988-05-27 1990-06-19 Warner-Lambert Company 4 or 5-(substituted piperazinylalkyl)-2-aminothiazoles as antipsychotic agents
US4954502A (en) * 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives

Also Published As

Publication number Publication date
CA2094703C (fr) 2002-03-26
JPH06501487A (ja) 1994-02-17
DE69116378T2 (de) 1996-06-13
CA2094703A1 (fr) 1992-05-06
ES2084996T3 (es) 1996-05-16
US5270312A (en) 1993-12-14
ATE132855T1 (de) 1996-01-15
WO1992007832A2 (fr) 1992-05-14
AU645873B2 (en) 1994-01-27
JP3064418B2 (ja) 2000-07-12
WO1992007832A3 (fr) 1992-06-11
EP0556329B1 (fr) 1996-01-10
GR3019490T3 (en) 1996-07-31
EP0556329A1 (fr) 1993-08-25
DE69116378D1 (de) 1996-02-22
AU9061991A (en) 1992-05-26

Similar Documents

Publication Publication Date Title
DK0556329T3 (da) Substituerede piperaziner som midler til behandling af centralnervesystemet
NO905253D0 (no) Fremgangsmaate for fremstilling av substituerte cykloheksanoler.
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
SE8503680D0 (sv) Indolderivat
DE69011318D1 (de) Diazinderivate als Angiotensin II Rezeptor Antagonisten.
NO941884L (no) 1,3-substituerte cykloalkener og cykloalkaner som sentralnervesystem-midler
DK0431579T3 (da) Substituerede cyclohexener som midler med virkning på centralnervesystemet
ES2104174T3 (es) Derivados de bencilamino, bencilamido y bencilimido ciclicos utilizados como agentes antipsicoticos.
MX10256A (es) Procedimiento para preparar nuevas 3-fenil-7h-tiazolo(3, 2-b) (1, 2, 4) triazin-7-onas.
DK0401093T3 (da) Hidtil ukendte pyrrolidonderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende disse
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
MX9101928A (es) Piperazinas substituidas como agentes del sistema nervioso central.
MX9206635A (es) Cicloalquenos y cicloalcanos 1,3-substituidos como agentes del sistema nervioso central.
MX9302225A (es) Cicloalquenos y cicloalcanos 1,3-substituidos como agentes del sistema nervioso central.
MX9101926A (es) Tetrahidropiridinas e hidroxipiperidinas substituidas como agentes del sistema nervioso central.